Results 151 to 160 of about 11,456 (188)

Comparison of SGLT2 Inhibitors for New-Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function. [PDF]

Diabetes Obes Metab
Nobayashi H, Satoh M, Hirose T, Nakayama S, Iwabe Y, Hashimoto H, Murakami T, Okada K, Mori T, Metoki H.   +9 more
europepmc   +1 more source

Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE. [PDF]

Kidney Int Rep
Miyamoto S, Heerspink HJL, de Zeeuw D, Sakamoto K, Yoshida M, Toyoda M, Suzuki D, Hatanaka T, Nakamura T, Kamei S, Murao S, Hida K, Ando S, Akai H, Takahashi Y, Kitada M, Sugano H, Nunoue T, Nakamura A, Sasaki M, Nakatou T, Fujimoto K, Kawanami D, Wada T, Miyatake N, Kuramoto H, Shikata K.   +26 more
europepmc   +1 more source

Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial. [PDF]

Diabetologia
Yan H, Liu J, Zhang Z, Chen S, Chang X, Jin H, Li X, Chen Y, Chen Y, Zeng M.   +9 more
europepmc   +1 more source

Dapagliflozin Beyond Glucose Lowering: Mechanisms of Renal and Systemic Protection. [PDF]

Pathophysiology
Wise ML, Alli AA.
europepmc   +1 more source

Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: From Metabolic Mechanisms to International Guidelines. [PDF]

Antioxidants (Basel)
Várkonyi T, Kupai K, Kang HL, Matusovits-Varga D, Priksz D, Várkonyi Á, Lengyel C, Pósa A.   +7 more
europepmc   +1 more source

Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity: A Mechanistic Review. [PDF]

Kidney360
Mathavan A, Mathavan A, Shah CV.
europepmc   +1 more source

Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching. [PDF]

PLoS One
Yuan Z, Jeffcoat CH, Ali SR, Sena AG, Schuemie MJ, Ryan PB, Fonseca SA.   +6 more
europepmc   +1 more source

SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes. [PDF]

Front Endocrinol (Lausanne)
Fang X, Li R, Liu S, Zou X, Zhong Y, Yang Y.   +5 more
europepmc   +1 more source

Renal and metabolic effects of semaglutide plus canagliflozin <i>vs</i> canagliflozin alone in type 2 diabetic nephropathy. [PDF]

World J Diabetes
Miao Y, He P, Wang DY, Yan L, Cao HX, Shao FM.   +5 more
europepmc   +1 more source

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications. [PDF]

Drugs Context
Manunta M, Bruno GM, Ferrantelli A, Ramirez RF, Nardi F.   +4 more
europepmc   +1 more source